Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Gang Yang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8641-5925; OpenAlex author ID A5100421187. Sources: OpenAlex.

Their work

Papers
44 (first author 13, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
60
Papers, trials and grants by year

2016: 1 paper · 2017: 2 papers · 2018: 6 papers · 2019: 6 papers · 2020: 8 papers · 2021: 11 papers · 2022: 1 paper · 2023: 4 papers · 2024: 3 papers · 2025: 2 papers

Papers 44

  1. Decipher the single-cell level responses to chemotherapy in pancreatic ductal adenocarcinoma by a cross-time context graph model. Co-author DOI 10.1016/j.canlet.2025.217751↗
  2. RNA binding protein DDX3X drives pancreatic cancer progression via the TLE2-MYL9 axis. Co-author DOI 10.1126/sciadv.adw9519↗
  3. Comprehensive multi-omics profiling identifies novel molecular subtypes of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.gendis.2023.101143↗
  4. FBXO32 Stimulates Protein Synthesis to Drive Pancreatic Cancer Progression and Metastasis. Co-author DOI 10.1158/0008-5472.can-23-3638↗
  5. CALB2 drives pancreatic cancer metastasis through inflammatory reprogramming of the tumor microenvironment. Co-author DOI 10.1186/s13046-024-03201-w↗
  6. Genomic analysis and filtration of novel prognostic biomarkers based on metabolic and immune subtypes in pancreatic cancer. Co-author DOI 10.1007/s13402-023-00836-3↗
  7. mTOR inhibitor, gemcitabine and PD-L1 antibody blockade combination therapy suppresses pancreatic cancer progression via metabolic reprogramming and immune mic… Co-author DOI 10.1016/j.canlet.2022.216020↗
  8. PRKRA promotes pancreatic cancer progression by upregulating MMP1 transcription via the NF-κB pathway. Co-author DOI 10.1016/j.heliyon.2023.e17194↗
  9. Epigenetic reprogramming-induced guanidinoacetic acid synthesis promotes pancreatic cancer metastasis and transcription-activating histone modifications. Co-author DOI 10.1186/s13046-023-02698-x↗
  10. HIF-1α-regulated stanniocalcin-1 mediates gemcitabine resistance in pancreatic ductal adenocarcinoma via PI3K/AKT signaling pathway. First author DOI 10.1002/mc.23420↗
  11. CREPT serves as a biomarker of poor survival in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s13402-020-00569-7↗
  12. The role of autophagy in pancreatic cancer progression. Co-author DOI 10.1016/j.bbcan.2021.188592↗
  13. Integrative Genomic Analysis of Gemcitabine Resistance in Pancreatic Cancer by Patient-derived Xenograft Models. Co-author DOI 10.1158/1078-0432.ccr-19-3975↗
  14. Targeting hypoxic tumor microenvironment in pancreatic cancer. First author DOI 10.1186/s13045-020-01030-w↗
  15. High-resolution Hi-C maps highlight multiscale 3D epigenome reprogramming during pancreatic cancer metastasis. Co-author DOI 10.1186/s13045-021-01131-0↗
  16. Preclinical models of pancreatic ductal adenocarcinoma: challenges and opportunities in the era of precision medicine. First author DOI 10.1186/s13046-020-01787-5↗
  17. Correction to: MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-021-02152-w↗
  18. Identification and Validation of Constructing the Prognostic Model With Four DNA Methylation-Driven Genes in Pancreatic Cancer. Co-author DOI 10.3389/fcell.2021.709669↗
  19. Comprehensive Analysis of Autophagy-Associated lncRNAs Reveal Potential Prognostic Prediction in Pancreatic Cancer. First author DOI 10.3389/fonc.2021.596573↗
  20. Suppression of the HBP Function Increases Pancreatic Cancer Cell Sensitivity to a Pan-RAS Inhibitor. Co-author DOI 10.3390/cells10020431↗
  21. The Role of Mitochondria in the Chemoresistance of Pancreatic Cancer Cells. Co-author DOI 10.3390/cells10030497↗
  22. The enhancement of glycolysis regulates pancreatic cancer metastasis. Co-author DOI 10.1007/s00018-019-03278-z↗
  23. Mechanistic target of rapamycin in the tumor microenvironment and its potential as a therapeutic target for pancreatic cancer. Co-author DOI 10.1016/j.canlet.2020.05.003↗
  24. Neoantigen-based immunotherapy in pancreatic ductal adenocarcinoma (PDAC). First author DOI 10.1016/j.canlet.2020.06.011↗
  25. Hexosamine pathway inhibition overcomes pancreatic cancer resistance to gemcitabine through unfolded protein response and EGFR-Akt pathway modulation. First author DOI 10.1038/s41388-020-1260-1↗
  26. OLR1 Promotes Pancreatic Cancer Metastasis via Increased c-Myc Expression and Transcription of HMGA2. Co-author DOI 10.1158/1541-7786.mcr-19-0718↗
  27. Novel therapeutic strategies and perspectives for metastatic pancreatic cancer: vaccine therapy is more than just a theory. First author DOI 10.1186/s12935-020-1147-9↗
  28. Metabolism of pancreatic cancer: paving the way to better anticancer strategies. First author DOI 10.1186/s12943-020-01169-7↗
  29. Reprogramming of Amino Acid Metabolism in Pancreatic Cancer: Recent Advances and Therapeutic Strategies. Co-author DOI 10.3389/fonc.2020.572722↗
  30. Novel discoveries targeting gemcitabine-based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination? First author DOI 10.1002/cam4.2384↗
  31. Integrated analysis of gene expression and methylation profiles of novel pancreatic cancer cell lines with highly metastatic activity. Co-author DOI 10.1007/s11427-018-9495-2↗
  32. Clinicopathological and prognostic significance of MKK4 and MKK7 in resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.humpath.2018.11.026↗
  33. Role of the microbiome in occurrence, development and treatment of pancreatic cancer. First author DOI 10.1186/s12943-019-1103-2↗
  34. Long noncoding RNA GSTM3TV2 upregulates LAT2 and OLR1 by competitively sponging let-7 to promote gemcitabine resistance in pancreatic cancer. Co-author DOI 10.1186/s13045-019-0777-7↗
  35. [The long coding RNA GSTM3TV2 acts an oncogene to promote chemoresistance in pancreatic cancer]. First author DOI 10.3760/cma.j.issn.0529-5815.2019.09.009↗
  36. Gemcitabine exhibits a suppressive effect on pancreatic cancer cell growth by regulating processing of PVT1 to miR1207. Co-author DOI 10.1002/1878-0261.12393↗
  37. NF-κB in pancreatic cancer: Its key role in chemoresistance. First author DOI 10.1016/j.canlet.2018.02.011↗
  38. Extracellular vesicles as mediators of the progression and chemoresistance of pancreatic cancer and their potential clinical applications. First author DOI 10.1186/s12943-017-0755-z↗
  39. Tumor microenvironment participates in metastasis of pancreatic cancer. Co-author DOI 10.1186/s12943-018-0858-1↗
  40. MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-018-0739-x↗
  41. LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer. Co-author DOI 10.1186/s13046-018-0947-4↗
  42. The underlying mechanisms of non-coding RNAs in the chemoresistance of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2017.02.020↗
  43. PD-1/PD-L1 and immunotherapy for pancreatic cancer. Co-author DOI 10.1016/j.canlet.2017.08.006↗
  44. Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.13212↗

Closest collaborators

The 25 strongest of 60 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Taiping Zhang · 36 shared papers, 2017–2025 · strength 4.37
  2. Lei You · 35 shared papers, 2017–2025 · strength 4.04
  3. Yupei Zhao · 30 shared papers, 2017–2024 · strength 3.34
  4. Fangyu Zhao · 19 shared papers, 2018–2023 · strength 2.17
  5. Mengyu Feng · 18 shared papers, 2017–2023 · strength 1.83
  6. Yueze Liu · 13 shared papers, 2019–2024 · strength 1.72
  7. Guangyu Chen · 12 shared papers, 2020–2025 · strength 1.65
  8. Zhe Cao · 15 shared papers, 2017–2024 · strength 1.63
  9. Jiangdong Qiu · 10 shared papers, 2019–2024 · strength 1.43
  10. Jinxin Tao · 8 shared papers, 2021–2025 · strength 1.31
  11. Jiangdong Qiu · 11 shared papers, 2018–2025 · strength 1.26
  12. Wenhao Luo · 9 shared papers, 2019–2024 · strength 1.19
  13. Jinshou Yang · 9 shared papers, 2019–2024 · strength 1.17
  14. Bo Ren · 7 shared papers, 2020–2024 · strength 1.02
  15. Guangbing Xiong · 9 shared papers, 2017–2021 · strength 0.82
  16. Jianchun Xiao · 6 shared papers, 2020–2024 · strength 0.79
  17. Hua Huang · 6 shared papers, 2018–2024 · strength 0.78
  18. Yuanyang Wang · 3 shared papers, 2021–2025 · strength 0.57
  19. Jie Ren · 3 shared papers, 2023–2024 · strength 0.55
  20. Dan Su · 3 shared papers, 2022–2023 · strength 0.50
  21. Jin Gu · 3 shared papers, 2020–2025 · strength 0.42
  22. Francesca Ricciardiello · 3 shared papers, 2020–2021 · strength 0.36
  23. Ferdinando Chiaradonna · 3 shared papers, 2020–2021 · strength 0.36
  24. Dan Su · 2 shared papers, 2024 · strength 0.35
  25. Hao Chen · 2 shared papers, 2020–2025 · strength 0.34

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.